A detailed history of Virtus Investment Advisers, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 2,068 shares of KRYS stock, worth $314,129. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,068
Holding current value
$314,129
% of portfolio
0.13%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$142.64 - $194.44 $294,979 - $402,101
2,068 New
2,068 $372,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.9B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Virtus Investment Advisers, Inc. Portfolio

Follow Virtus Investment Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.